David Lacey, M.D., is the former senior vice president of discovery research at Amgen. Throughout a distinguished career, Dr. Lacey has focused on the use of science and technology to help create new medicines that make a difference in the lives of patients worldwide.
He joined Amgen in 1994, Lacey and was responsible for a number of key research programs and has helped to make significant advancements in the understanding of bone biology. He played an important role in the discovery of osteoprotegerin (OPG) and in the understanding of the RANK/RANK Ligand pathway in bone metabolism that paved the way for the development of denosumab (Prolia).
Before joining Amgen, Lacey was on the faculty at Washington University in St. Louis, Mo., where he taught pathology residents and medical students and pursued NIH-funded research in bone cell biology. Lacey received his M.D. from the University of Colorado and is a member of the American Association for the Advancement of Science, the American Society for Bone and Mineral Research, and the International Bone and Mineral Society.
Top innovative news from 2010:
• Amgen’s 147 trial was the first study to ever show a delay in the onset of bone metastases in men with prostate cancer, for the... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.